<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Elshikha AS</submitter><funding>Grifols Inc.</funding><funding>Egypt Government Scholarship</funding><funding>University of Florida Foundation</funding><pagination>E1341</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6780888</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(9)</volume><pubmed_abstract>Diffuse alveolar hemorrhage (DAH) is a fatal complication in patients with lupus. DAH can be induced in B6 mice by an intraperitoneal injection of pristane. Since human alpha-1-antitrypsin (hAAT) is an anti-inflammatory and immuno-regulatory protein, we investigated the protective effect of hAAT against pristane-induced DAH in B6 mice and hAAT transgenic (hAAT-Tg) mice. We first showed that hAAT Tg expression lowers TNF-α production in B cells, as well as CD4+ T cells in untreated mice. Conversely, the frequency of regulatory CD4+CD25+ and CD4+CD25-IL-10+ cells was significantly higher in hAAT-Tg than in B6 mice. This confirmed the anti-inflammatory effect of hAAT that was observed even at steady state. One week after a pristane injection, the frequency of peritoneal Ly6C&lt;sup>hi&lt;/sup> inflammatory monocytes and neutrophils in hAAT-Tg mice was significantly lower than that in B6 mice. Importantly, pristane-induced DAH was completely prevented in hAAT-Tg mice and this was associated with a modulation of anti- to pro-inflammatory myeloid cell ratio/balance. We also showed that treatment with hAAT decreased the severity of DAH in B6 mice. These results showed for the first time that hAAT has a therapeutic potential for the treatment of DAH.</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice.</pubmed_title><pmcid>PMC6780888</pmcid><funding_grant_id>89815</funding_grant_id><funding_grant_id>62632</funding_grant_id><funding_grant_id>71916</funding_grant_id><pubmed_authors>van der Meijden-Erkelens L</pubmed_authors><pubmed_authors>Chen MJ</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Abboud G</pubmed_authors><pubmed_authors>Elshikha AS</pubmed_authors><pubmed_authors>Ponjee G</pubmed_authors><pubmed_authors>Zeumer L</pubmed_authors><pubmed_authors>Song S</pubmed_authors><pubmed_authors>Morel L</pubmed_authors><pubmed_authors>Satoh M</pubmed_authors><pubmed_authors>Yuan Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice.</name><description>Diffuse alveolar hemorrhage (DAH) is a fatal complication in patients with lupus. DAH can be induced in B6 mice by an intraperitoneal injection of pristane. Since human alpha-1-antitrypsin (hAAT) is an anti-inflammatory and immuno-regulatory protein, we investigated the protective effect of hAAT against pristane-induced DAH in B6 mice and hAAT transgenic (hAAT-Tg) mice. We first showed that hAAT Tg expression lowers TNF-α production in B cells, as well as CD4+ T cells in untreated mice. Conversely, the frequency of regulatory CD4+CD25+ and CD4+CD25-IL-10+ cells was significantly higher in hAAT-Tg than in B6 mice. This confirmed the anti-inflammatory effect of hAAT that was observed even at steady state. One week after a pristane injection, the frequency of peritoneal Ly6C&lt;sup>hi&lt;/sup> inflammatory monocytes and neutrophils in hAAT-Tg mice was significantly lower than that in B6 mice. Importantly, pristane-induced DAH was completely prevented in hAAT-Tg mice and this was associated with a modulation of anti- to pro-inflammatory myeloid cell ratio/balance. We also showed that treatment with hAAT decreased the severity of DAH in B6 mice. These results showed for the first time that hAAT has a therapeutic potential for the treatment of DAH.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Aug</publication><modification>2026-05-06T23:00:33.635Z</modification><creation>2019-11-07T08:04:27Z</creation></dates><accession>S-EPMC6780888</accession><cross_references><pubmed>31470606</pubmed><doi>10.3390/jcm8091341</doi></cross_references></HashMap>